Compare TG Therapeutics Inc (TGTX) vs Weyerhaeuser Company Common Stock (WY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Weyerhaeuser Company Common Stock — how do they compare? TG Therapeutics Inc trades at $54.13 (market cap $8.32B), while Weyerhaeuser Company Common Stock trades at $19.16 (market cap $13.62B). The key difference: Weyerhaeuser Company Common Stock is the larger of the two by market cap, and Weyerhaeuser Company Common Stock pays a 4.44% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WY | |
|---|---|---|
Market Cap | $8.32B | $13.62B |
Volume | 1,285,303 | 8,637,043 |
Sector | Health | Real Estate |
52-Week High | $59.06 | $27.10 |
52-Week Low | $26.94 | $18.47 |
Typical Hold Time | 16 Days | — |
Enterprise Value | $8.52B | $18.54B |
Dividend Yield | — | 4.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.34, down 1.68% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results missed expectations. Analyst sentiment is overwhelmingly positive, with 11 buy ratings and a consensus price target of $80.50, while recent news highlights Briumvi's market share gains and potential acquisition interest.
The outlook for TGTX is favorable, driven by Briumvi's expanding multiple sclerosis market share and raised 2026 revenue guidance to $950 million. Key risks include ongoing earnings misses, a high EV/EBITDA ratio of 61.15, and a shareholder litigation investigation. Upside potential remains if the company meets future earnings targets and sustains its growth trajectory.
Weyerhaeuser (WY) trades at $18.97, up 0.16% with neutral technical signals. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while fundamentals reveal modest profitability with 6.89% net margin and 4.97% ROE. Recent news highlights institutional accumulation and upcoming Q3 earnings on October 29. The company maintains stable revenue at $6.9B but faces cash flow challenges with negative net cash flow of $203M in 2025.
Weyerhaeuser presents a mixed outlook with analyst consensus favoring bullish sentiment (52% buy ratings) and a $29.33 price target suggesting 55% upside. However, risks include weak dividend coverage, high leverage at 5x, and sensitivity to interest rates and housing market cycles. The stock's current proximity to 52-week lows offers potential value but requires careful monitoring of lumber demand recovery and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Weyerhaeuser Company Common Stock
Weyerhaeuser Company is a timberland-focused real estate investment trust (REIT) that owns and manages more than 10 million acres of timberland in US, in addition to timberlands under long-term license in Canada. The company also manufactures wood products, including lumber, oriented strand board, and engineered wood.
Read more on WY →
